Cryocompression Use by Multidisciplinary Teams May Help Gynecologic Cancer QOL

Video

Medical oncologists and gynecologic oncologists alike have a shared responsibility to help treat symptoms of neuropathy in patients undergoing chemotherapy for gynecologic cancer, according to an expert from Duke University Medical Center.

It is “everyone’s job” in a multidisciplinary team to monitor and adjust chemotherapy doses in patients with gynecologic cancers to prevent the occurrence of adverse effects including peripheral neuropathy, according to Mary Katherine Montes de Oca, MD.

At The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, CancerNetwork® spoke with Montes de Oca, an Obstetrics and Gynecology resident at Duke University Medical Center, about how cryocompression can be used within a multidisciplinary team that manages gynecologic cancers, including medical oncologists, gynecologic oncologists, advanced practice providers, and neurologists.

According to Montes de Oca, a neurologist specializing in neuropathy helped with carrying out a self-controlled trial evaluating the use cryocompression to prevent peripheral neuropathy induced by chemotherapy in patients with gynecologic cancers. Additionally, she stated that this intervention may prevent neuropathy completely, suggesting that those who prescribe and administer chemotherapy to patients may recommend cryocompression to help improve their quality of life.

Transcript:

We partnered with a neurologist to help us design this study, particularly somebody who specialized in neuropathy and how to diagnose neuropathy. But any time that we’re prescribing these treatments, a lot of places have a multidisciplinary team with medical oncologists, gynecologic oncologists, and [advanced practice practitioners].

It’s everyone’s job to both recognize when patients are developing neuropathy so that we can adequately change the chemotherapy dose to prevent adverse [effects]. However, this intervention can really help us to prevent their neuropathy in the first place. There are various [practitioners] who are prescribing the chemotherapy and can mention this intervention to the patients to really improve their quality of life.

Reference

Montes de Oca MK, Unnithan S, Erkanli AE, et al. Use of cryocompression to reduce peripheral neuropathy in gynecologic cancer: a randomized controlled trial. Presented at: 2023 SGO Annual Meeting on Women’s Cancer; March 25-28, 2023; Tampa, Florida.

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Related Content